Literature DB >> 6092708

Structural characterization of virion proteins and genomic RNA of human parainfluenza virus 3.

D G Storey, K Dimock, C Y Kang.   

Abstract

The virion proteins and genomic RNA of human parainfluenza virus 3 have been characterized. The virion contains seven major and two minor proteins. Three proteins of 195 X 10(3) molecular weight (195K), 87K, and 67K are associated with the nucleocapsid of the virion and have been designated L, P, and NP, respectively. Three proteins can be labeled with [14C]glucosamine and have molecular weights of 69K, 60K, and 46K. We have designated these proteins as HN, F0, and F1, respectively. HN protein has interchain disulfide bonds, but does not participate in disulfide bonding to form homomultimeric forms. F1 appears to be derived from a complex, F1,2, that has an electrophoretic mobility similar to that of F0 under nonreducing conditions. A protein of 35K is associated with the envelope components of the virion and aggregates under low-salt conditions; this protein has been designated M. The genome of human parainfluenza virus 3 is a linear RNA molecule with a molecular weight of approximately 4.6 X 10(6).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6092708      PMCID: PMC254594     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Sendai virus-induced transcriptase from infected cells: polypeptides in the transcriptive complex.

Authors:  H O Stone; D W Kingsbury; R W Darlington
Journal:  J Virol       Date:  1972-11       Impact factor: 5.103

2.  Isolation of paramyxovirus glycoproteins. Association of both hemagglutinating and neuraminidase activities with the larger SV5 glycoprotein.

Authors:  A Scheid; L A Caliguiri; R W Compans; P W Choppin
Journal:  Virology       Date:  1972-12       Impact factor: 3.616

3.  Replication of Sendai virus. I. Comparison of the viral RNA and virus-specific RNA synthesis with Newcastle disease virus.

Authors:  C D Blair; W S Robinson
Journal:  Virology       Date:  1968-08       Impact factor: 3.616

4.  The nucleic acid of Sendai virus and ribonucleic acid synthesis in cells infected by Sendai virus.

Authors:  R D Barry; A G Bukrinskaya
Journal:  J Gen Virol       Date:  1968-01       Impact factor: 3.891

5.  Proteins and glycoproteins of paramyxoviruses: a comparison of simian virus 5, Newcastle disease virus, and Sendai virus.

Authors:  W E Mountcastle; R W Compans; P W Choppin
Journal:  J Virol       Date:  1971-01       Impact factor: 5.103

6.  Epidemiologic patterns of acute lower respiratory disease of children in a pediatric group practice.

Authors:  W P Glezen; F A Loda; W A Clyde; R J Senior; C I Sheaffer; W G Conley; F W Denny
Journal:  J Pediatr       Date:  1971-03       Impact factor: 4.406

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  Properties of incomplete Sendai virions and subgenomic viral RNAs.

Authors:  D W Kingsbury; A Portner; R W Darlington
Journal:  Virology       Date:  1970-12       Impact factor: 3.616

9.  Isolation and purification of the envelope proteins of Newcastle disease virus.

Authors:  A Scheid; P W Choppin
Journal:  J Virol       Date:  1973-02       Impact factor: 5.103

10.  Nucleocapsid protein subunits of simian virus 5, Newcastle disease virus, and Sendai virus.

Authors:  W E Mountcastle; R W Compans; L A Caliguiri; P W Choppin
Journal:  J Virol       Date:  1970-11       Impact factor: 5.103

View more
  23 in total

1.  Human parainfluenza virus type 3 (HPIV-3): construction and rescue of an infectious, recombinant virus expressing the enhanced green fluorescent protein (EGFP).

Authors:  Jason P Roth; Joseph K-K Li; Dale L Barnard
Journal:  Curr Protoc Microbiol       Date:  2010-05

2.  Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.

Authors:  M K Spriggs; B R Murphy; G A Prince; R A Olmsted; P L Collins
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

3.  Localization of the labile disulfide bond between SU and TM of the murine leukemia virus envelope protein complex to a highly conserved CWLC motif in SU that resembles the active-site sequence of thiol-disulfide exchange enzymes.

Authors:  A Pinter; R Kopelman; Z Li; S C Kayman; D A Sanders
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies.

Authors:  K J Coelingh; C C Winter; B R Murphy; J M Rice; P C Kimball; R A Olmsted; P L Collins
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

5.  Characterization of an in vitro system for the synthesis of mRNA from human parainfluenza virus type 3.

Authors:  B P De; M S Galinski; A K Banerjee
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

6.  Intracellular synthesis of human parainfluenza type 3 virus-specified polypeptides.

Authors:  S L Wechsler; D M Lambert; M S Galinski; M W Pons
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

7.  Proteins associated with human parainfluenza virus type 3.

Authors:  R C Jambou; N Elango; S Venkatesan
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

8.  3'-Terminal sequence of human parainfluenza virus 3 genomic RNA.

Authors:  K Dimock; E W Rud; C Y Kang
Journal:  Nucleic Acids Res       Date:  1986-06-11       Impact factor: 16.971

9.  Characterization of a live, attenuated human parainfluenza type 3 virus candidate vaccine strain.

Authors:  R Ray; K Meyer; F K Newman; R B Belshe
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

10.  Temperature-sensitive phenotype of the human parainfluenza virus type 3 candidate vaccine strain (cp45) correlates with a defect in the L gene.

Authors:  R Ray; M S Galinski; B R Heminway; K Meyer; F K Newman; R B Belshe
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.